1Associate Professor, Department of Internal Medicine No.2, V. I. Vernadsky Crimean Federal University, Simferopol, Russia
2Assistant, Department of Internal Medicine No.1, V. I. Vernadsky Crimean Federal University, Simferopol, Russia
3Department of Internal Medicine No.2, V. I. Vernadsky Crimean Federal University, Simferopol, Russia
4Associate Professor, Department of Oncology, V. I. Vernadsky Crimean Federal University, Simferopol, Russia
5Associate Professor, Department of Propedeutics of Dentistry, V. I. Vernadsky Crimean Federal University, Simferopol, Russia
*Corresponding Author: Vitalii B. Kaliberdenko, MD, PhD, Associate Professor, Department of Internal Medicine No.2, V. I. Vernadsky Crimean Federal University, Simferopol, Russia, Phone: +7(978)1222851, Email: vit_boris@mail.ru
Online published on 13 November, 2019.
True polycythemia is a clonal myeloproliferative process, from the group of Ph-negative myeloproliferative diseases, developing at the level of the stem hematopoietic cell with a subsequent violation of the proliferation and differentiation of hematopoietic cells. Purpose of the study is to analyze the features of the development of cardiovascular complications in patients with true polycythemia and to establishment of correlation between age of the patients, duration of the disease and the effectiveness of their symptomatic therapy. Materials and methods-An Assessment of the evolution of complications in cardiovascular system with patients suffering from polycythemiavera was evaluated, and a correlation was established between age of the patients, duration of illness, and the effectiveness of their symptomatic therapy. An analysis of 30 patients suffering from polycythemiavera-23 men and 7 women were studied. Results-The main complications that develop as syndromes and symptoms in patients suffering from polycythemiavera were found and the probability of development of thrombotic complications were assessed. The possibility of progressing of complications in cardiovascular system were as follows, symptomatic arterial hypertension, coronary artery diseases(CAD) and hypertension, increases with age of the patients and with the length of the disease.
Polycythemiavera (Erythemia, Vaquez-osler disease), Cardio-vascular complications, thrombotic complications, Myeloroliferative disease, JAK2
